Clinical trial
YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease
NCT00141960 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease
- Lead sponsor
- Astellas Pharma Inc
- Phase
- Phase 2/3
- Overall status
- Completed
- Start date
- September 30, 2005
- Completion date
- Not reported
- Enrollment
- 480
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.